Inovio Pharmaceuticals Inc. (INO): Price and Financial Metrics


Inovio Pharmaceuticals Inc. (INO): $7.79

-0.35 (-4.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

INO POWR Grades


  • INO scores best on the Value dimension, with a Value rank ahead of 53.07% of US stocks.
  • INO's strongest trending metric is Quality; it's been moving down over the last 47 weeks.
  • INO ranks lowest in Sentiment; there it ranks in the 0th percentile.

INO Stock Summary

  • With a price/sales ratio of 252.34, Inovio Pharmaceuticals Inc has a higher such ratio than 98.24% of stocks in our set.
  • With a year-over-year growth in debt of -66.55%, Inovio Pharmaceuticals Inc's debt growth rate surpasses only 5.5% of about US stocks.
  • As for revenue growth, note that INO's revenue has grown 135.72% over the past 12 months; that beats the revenue growth of 95.02% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Inovio Pharmaceuticals Inc are VIR, PTGX, SGMO, SYRS, and RNA.
  • Visit INO's SEC page to see the company's official filings. To visit the company's web site, go to www.inovio.com.

INO Valuation Summary

  • In comparison to the median Healthcare stock, INO's price/sales ratio is 2378.41% higher, now standing at 281.3.
  • INO's price/sales ratio has moved up 277.6 over the prior 243 months.
  • INO's price/earnings ratio has moved down 10.8 over the prior 243 months.

Below are key valuation metrics over time for INO.

Stock Date P/S P/B P/E EV/EBIT
INO 2021-08-31 281.3 3.6 -12.8 -13.0
INO 2021-08-30 281.3 3.6 -12.8 -13.0
INO 2021-08-27 285.9 3.6 -13.0 -13.2
INO 2021-08-26 283.3 3.6 -12.9 -13.1
INO 2021-08-25 274.8 3.5 -12.5 -12.7
INO 2021-08-24 272.8 3.5 -12.4 -12.6

INO Growth Metrics

  • The 2 year cash and equivalents growth rate now stands at 322.43%.
  • Its year over year price growth rate is now at -43.95%.
  • Its 5 year net cashflow from operations growth rate is now at -561.22%.
Over the past 70 months, INO's revenue has gone down $30,632,954.

The table below shows INO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 6.460703 -256.7015 -141.7091
2021-03-31 6.455066 -205.3938 -188.2722
2020-12-31 7.41122 -177.979 -166.4112
2020-09-30 2.110127 -140.4999 -179.7348
2020-06-30 2.740812 -94.07501 -221.9968
2020-03-31 2.609298 -90.84851 -122.681

INO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INO has a Quality Grade of D, ranking ahead of 15.86% of graded US stocks.
  • INO's asset turnover comes in at 0.012 -- ranking 165th of 182 Medical Equipment stocks.
  • POAI, EYES, and PETV are the stocks whose asset turnover ratios are most correlated with INO.

The table below shows INO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.012 1 -0.344
2021-03-31 0.012 1 -0.528
2020-12-31 0.017 1 -0.595
2020-09-30 0.006 1 -0.704
2020-06-30 0.010 1 -0.961
2020-03-31 0.013 1 -0.567

INO Price Target

For more insight on analysts targets of INO, see our INO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.71 Average Broker Recommendation 1.94 (Hold)

INO Stock Price Chart Interactive Chart >

Price chart for INO

INO Price/Volume Stats

Current price $7.79 52-week high $19.00
Prev. close $8.14 52-week low $5.81
Day low $7.68 Volume 3,662,412
Day high $8.13 Avg. volume 9,328,083
50-day MA $8.44 Dividend yield N/A
200-day MA $9.30 Market Cap 1.64B

Inovio Pharmaceuticals Inc. (INO) Company Bio


Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Inovio leverages its optimized plasmid design and delivery technology to develop DNA medicines to potentially treat and prevent diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The company has more than 2,000 patients receiving Inovio DNA medicines in more than 7,000 clinical trial applications. Inovio’s corporate headquarters is in Plymouth Meeting, Pennsylvania with research & development and manufacturing facilities in San Diego, California. Dr. J. Joseph Kim serves as the company’s President and Chief Executive Officer.


INO Latest News Stream


Event/Time News Detail
Loading, please wait...

INO Latest Social Stream


Loading social stream, please wait...

View Full INO Social Stream

Latest INO News From Around the Web

Below are the latest news stories about Inovio Pharmaceuticals Inc that investors may wish to consider to help them evaluate INO as an investment opportunity.

Vaccines Market to Soar at 10.7 % CAGR and Hit USD 104.87 Billion till 2027 Backed by Several Immunization Programs Funded by Governments: Fortune Business Insights

Top Players Covered in the Vaccines Market Research Report are GlaxoSmithKline plc., Sanofi, Pfizer Inc., Merck & Co., Inc., Novartis AG, Emergent BioSolutions, Inc., CSL Limited, Inovio Pharmaceuticals, Inc., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation and other key market players. Top Players Covered in the Vaccines Market Research Report are GlaxoSmithKline plc., Sanofi, Pfizer Inc., Merck & Co., Inc., Novartis AG, Emergent BioSolutions, Inc., CSL Limited, Inovio Pharmaceuticals, Inc., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation and other key market players.

Intrado Digital Media | September 16, 2021

Is Inovio Stock A Buy After Brazil OKs Phase 3 Test For Covid Vaccine?

Is INO stock a buy after Brazil's national health agency granted Inovio permission to begin a Phase 2 and Phase 3 Covid vaccine test?

Yahoo | September 15, 2021

Inovio Pharmaceuticals Inc. stock falls Friday, underperforms market

Inovio Pharmaceuticals Inc. stock falls Friday, underperforms market MarketWatch

MarketWatch | September 14, 2021

Inovio Pharmaceuticals Inc (INO): Price Now Near $7.78; Daily Chart Shows An Uptrend on 100 Day Basis

It''s been a feast for bears operating on the daily timeframe, as ino has now gone down 4 of the past 5 days. The post Inovio Pharmaceuticals Inc (INO): Price Now Near $7.78; Daily Chart Shows An Uptrend on 100 Day Basis appeared first on ETF Daily News .

ETF Daily News | September 14, 2021

Inovio Downgraded by BofA on Limited Covid Opportunity

Company's COVID vaccine candidate has lower likely returns than other therapies with longer timelines, BofA said.

Yahoo | September 10, 2021

Read More 'INO' Stories Here

INO Price Returns

1-mo -3.59%
3-mo -10.46%
6-mo -13.25%
1-year -54.18%
3-year 64.69%
5-year -20.51%
YTD -11.98%
2020 168.18%
2019 -17.50%
2018 -3.15%
2017 -40.49%
2016 3.27%

Continue Researching INO

Want to see what other sources are saying about Inovio Pharmaceuticals Inc's financials and stock price? Try the links below:

Inovio Pharmaceuticals Inc (INO) Stock Price | Nasdaq
Inovio Pharmaceuticals Inc (INO) Stock Quote, History and News - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7175 seconds.